Cardiac Dimensions Raises $53M to Advance Heart Failure Device
The funding will support global commercialisation and a major U.S. trial of the Carillon system for patients with functional mitral regurgitation.
Elena Whitmore 
Focus on minimally invasive heart failure therapy
Cardiac Dimensions, a company focused on less invasive solutions for treating heart failure, has closed a $53 million Series E funding round. The financing, led by Ally Bridge Group, will enable the company to complete a pivotal U.S. clinical trial and expand global access to its Carillon Mitral Contour System, a device designed to treat functional mitral regurgitation (FMR).
Joining the round were new investor Claret Capital Partners and existing backers including Hostplus, M.H. Carnegie, Horizon 3 Healthcare, Lumira Ventures, and a confidential strategic investor. The company has now raised approximately $214.76 million to date, having previously secured $35 million in Series D funding in January 2023 and $39 million in Series B funding in 2018.
A targeted solution for a common complication
The Carillon Mitral Contour System offers a minimally invasive approach to treating FMR, a condition that affects more than half of all heart failure patients. The system reshapes the mitral valve annulus, reducing regurgitation while preserving the native valve structure. Unlike other devices, it does not require open-heart surgery and does not interfere with potential future treatments.
Founded in 2001 by Scott Wolf, Cardiac Dimensions has concentrated on filling critical gaps in heart failure treatment. The Carillon system is designed to improve cardiac function by addressing the primary cause of FMR in patients with moderate to severe mitral regurgitation.
Clinical data has supported its effectiveness. One study led by Prof. Dr. Andreas Hagendorff reported that 83% of patients showed an acute reduction in regurgitant fraction following implantation, as confirmed by echocardiography. The therapy has also been shown to support favourable left ventricular remodelling, increase patient quality of life, and improve survival rates.
Strategic trial and international goals
The newly secured funds will primarily support the completion of the EMPOWER Trial, a randomised, sham-controlled U.S. study that will help validate the safety and efficacy of the Carillon system. The trial stands out as the only blinded investigation of its kind in the mitral valve treatment space. It draws on insights from more than 250 patients in earlier trials and includes independent data monitoring, core lab assessments, and external safety oversight.
According to Rick Wypych, president and CEO of Cardiac Dimensions, the company is "uniquely positioned to provide a safe, simple, and effective solution" for patients with FMR. He added that the investment signals strong backing from both new and existing stakeholders.
Steve Plachtyna of Ally Bridge Group, who joined the company’s board following the funding round, commented, “We have been impressed with the progress the company has made over the past several years in both their clinical efforts and their expansion of commercial sales outside the U.S.”
With operations in Kirkland, Frankfurt, and Sydney, Cardiac Dimensions is aiming to strengthen its presence across global markets while continuing to generate clinical evidence for its lead product. The company’s long-term goal is to establish minimally invasive therapies like the Carillon system as standard treatments for heart failure linked to FMR.
